Another emerging therapeutic strategy for GBA1-associated PD is treatment with pharmacological chaperones, small molecules that bind to mutant proteins in the ER and stabilize their native folding, thus enabling them to leave the ER [118, 119]. The gene discussed is GBA1; the disease is Parkinson disease.